

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Orbifloxacin Liquid Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification


#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2      H361d: Suspected of damaging the unborn child.  
Specific target organ toxicity - repeated exposure, Category 2, Eye      H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
**Storage:**  
P405 Store locked up.

Hazardous components which must be listed on the label:  
Orbifloxacin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 3 - < 10
Lactic acid	50-21-5 200-018-0	Skin Corr. 1C; H314 Eye Dam. 1; H318 EUH071  specific concentration limit Eye Irrit. 2; H319 1 - < 3 %	>= 1 - < 3

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

Sodium hydroxide	1310-73-2 215-185-5 011-002-00-6	Met. Corr. 1; H290 Skin Corr. 1A; H314 Eye Dam. 1; H318 EUH014, EUH071  specific concentra- tion limit Skin Corr. 1A; H314 >= 5 % Skin Corr. 1B; H314 2 - < 5 % Skin Irrit. 2; H315 0,5 - < 2 % Eye Irrit. 2; H319 0,5 - < 2 % EUH071 >= 2 %	>= 1 - < 2
------------------	--	---	------------

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure if swallowed.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA	25 ppm 79 mg/m <sup>3</sup>	FOR-2011-12-06-1358
Orbifloxacin	113617-63-3	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWA (respirable dust)	1,5 mg/m <sup>3</sup> (Silica)	FOR-2011-12-06-1358
Sodium hydroxide	1310-73-2	T	2 mg/m <sup>3</sup>	FOR-2011-12-06-1358

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local effects	10 mg/m <sup>3</sup>
	Workers	Inhalation	Long-term systemic effects	168 mg/m <sup>3</sup>
	Consumers	Inhalation	Long-term local effects	10 mg/m <sup>3</sup>
	Consumers	Inhalation	Long-term systemic effects	50 mg/m <sup>3</sup>
Silicon dioxide	Workers	Inhalation	Long-term systemic effects	4 mg/m <sup>3</sup>
Sodium hydroxide	Consumers	Inhalation	Long-term local effects	1 mg/m <sup>3</sup>
	Workers	Inhalation	Long-term local effects	1 mg/m <sup>3</sup>

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57,2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

#### Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection  
Material : Chemical-resistant gloves
- Skin and body protection : Work uniform or laboratory coat.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to NS EN 14387
- Filter type : Combined particulates and organic vapour type (A-P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

- Physical state : suspension
- Colour : light brown
- Odour : odourless
- Odour Threshold : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flammability (solid, gas) : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : None known.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3.000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2.000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg  
Symptoms: Vomiting  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg  
Application Route: Intramuscular

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg  
Application Route: Intravenous

### Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Assessment: Corrosive to the respiratory tract.  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

### Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

### Skin corrosion/irritation

Not classified based on available information.

### Product:

Species : Rabbit  
Result : No skin irritation

### Components:

#### Orbifloxacin:

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

### Lactic acid:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Corrosive after 1 to 4 hours of exposure  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

### **Sodium hydroxide:**

Result : Corrosive after 3 minutes or less of exposure

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Product:**

Species : Rabbit  
Result : Mild eye irritation

### **Components:**

#### **Orbifloxacin:**

Species : Rabbit  
Method : Draize Test  
Result : Mild eye irritation

#### **Lactic acid:**

Species : Chicken eye  
Remarks : Based on data from similar materials  
Result : Irreversible effects on the eye

#### **Sodium hydroxide:**

Result : Irreversible effects on the eye  
Remarks : Based on skin corrosivity.

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Product:**

Test Type : Magnusson-Kligman-Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

### **Components:**

#### **Orbifloxacin:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

### Lactic acid:

Test Type : Buehler Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

### Sodium hydroxide:

Test Type : Human repeat insult patch test (HRIPT)  
Exposure routes : Skin contact  
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: equivocal

Test Type: Mouse Lymphoma  
Result: positive

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative  
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

#### Components:

##### **Orbifloxacin:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

##### **Lactic acid:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative  
Remarks : Based on data from similar materials

### Reproductive toxicity

Suspected of damaging the unborn child.

#### Components:

##### **Orbifloxacin:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 50 mg/kg body weight  
Early Embryonic Development: NOAEL: 50 mg/kg body weight  
Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight  
Result: No teratogenic effects, Embryotoxic effects and ad-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

verse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 20 mg/kg body weight  
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight  
Result: No effects on early embryonic development, Embryo-toxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development  
Species: Dog  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight  
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Lactic acid:

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

### Product:

Target Organs : Eye  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Product:

Species : Dog  
NOAEL : 22,5 mg/kg  
LOAEL : 37,5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Symptoms : Gastrointestinal disturbance

Species : Dog

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

LOAEL : 75 mg/kg  
Application Route : Oral  
Exposure time : 10 Days  
Symptoms : Salivation, Gastrointestinal disturbance, Vomiting

Species : Cat  
LOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Target Organs : Eye  
Symptoms : Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

### Components:

#### **Orbifloxacin:**

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 80 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse  
NOAEL : 80 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

Species : Juvenile dog  
NOAEL : 50 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 14 Days  
Target Organs : Heart, Bone  
Symptoms : Gastrointestinal disturbance  
Remarks : mortality observed

Species : Juvenile dog  
NOAEL : 2 mg/kg  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 37,5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days

Species : Cat  
NOAEL : 7,5 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

LOAEL : 22,5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Gastrointestinal disturbance

### Lactic acid:

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks  
Remarks : Based on data from similar materials

Species : Rat  
LOAEL : 886 mg/kg  
Application Route : Skin contact  
Exposure time : 13 Weeks

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

#### Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
Remarks: May cause photosensitisation.

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

---



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50 : > 10 - 100 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209  
Remarks: Based on data from similar materials

### 12.2 Persistence and degradability

#### Components:

#### **Lactic acid:**

Biodegradability : Result: Not readily biodegradable.  
Remarks: Based on data from similar materials

### 12.3 Bioaccumulative potential

#### Components:

#### **Lactic acid:**

Partition coefficient: n-octanol/water : log Pow: -0,62

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components consid-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

- Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
- 

## SECTION 14: Transport information

### 14.1 UN number or ID number

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

- ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version 4.2      Revision Date: 30.09.2023      SDS Number: 785875-00019      Date of last issue: 04.04.2023  
Date of first issue: 28.06.2016

---

**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA (Cargo)** : Not regulated as a dangerous good

**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

---

### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H290	:	May be corrosive to metals.
H314	:	Causes severe skin burns and eye damage.
H318	:	Causes serious eye damage.
H361d	:	Suspected of damaging the unborn child.
EUH014	:	Reacts violently with water.
EUH071	:	Corrosive to the respiratory tract.

### Full text of other abbreviations

Eye Dam.	:	Serious eye damage
Met. Corr.	:	Corrosive to metals
Repr.	:	Reproductive toxicity
Skin Corr.	:	Skin corrosion
FOR-2011-12-06-1358	:	Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA	:	Long term exposure limit
FOR-2011-12-06-1358 / T	:	Ceiling

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good La-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.2	30.09.2023	785875-00019	Date of first issue: 28.06.2016

laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 2	H361d
STOT RE 2	H373

### Classification procedure:

Calculation method
Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN